Author, as appears in the article.: Folch, J; Ettcheto, M; Petrov, D; Abad, S; Pedros, I; Marin, M; Olloquequi, J; Camins, A
Department: Bioquímica i Biotecnologia
URV's Author/s: Folch Lopez, Jaume
Keywords: Solanezumab Humans Hipótesis amiloidea Gamma-secretase Gamma-secretasa Beta-secretase Beta-secretasa Beta-amyloid Beta-amiloide App protein, human Antibodies, monoclonal, humanized Amyloid precursor protein secretases Amyloid hypotheses Amyloid beta-protein precursor Amyloid beta-peptides Alzheimer disease Alzheimer gamma-secretase gamma-secretasa beta-secretase beta-secretasa beta-amyloid beta-amiloide amyloid hypotheses alzheimer disease alzheimer
Abstract: Alzheimer disease (AD) is a major neurodegenerative disorder which eventually results in total intellectual disability. The high global prevalence and the socioeconomic burden associated with the disease pose major challenges for public health in the 21st century. In this review we focus on both existing treatments and the therapies being developed, which principally target the β-amyloid protein. DISCUSSION: The amyloidogenic hypothesis proposes that β-amyloid plays a key role in AD. Several pharmacological approaches aim to reduce the formation of β-amyloid peptides by inhibiting the β-secretase and γ-secretase enzymes. In addition, both passive and active immunotherapies have been developed for the purpose of inhibiting β-amyloid peptide aggregation. CONCLUSIONS: Progress in identifying the molecular basis of AD may provide better models for understanding the causes of this neurodegenerative disease. The lack of efficacy of solanezumab (a humanised monoclonal antibody that promotes β-amyloid clearance in the brain), demonstrated by 2 recent Phase III clinical trials in patients with mild AD, suggests that the amyloidogenic hypothesis needs to be revised.
Thematic Areas: Psicología Neurology (clinical) Medicine (miscellaneous) Medicina ii Medicina i General medicine Clinical neurology
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 15781968
Author's mail: jaume.folch@urv.cat
Author identifier: 0000-0002-5051-8858
Record's date: 2024-10-19
Papper version: info:eu-repo/semantics/publishedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Neurologia. 33 (1): 47-58
APA: Folch, J; Ettcheto, M; Petrov, D; Abad, S; Pedros, I; Marin, M; Olloquequi, J; Camins, A (2018). Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. [Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein].. Neurologia, 33(1), 47-58. DOI: 10.1016/j.nrl.2015.03.012
Entity: Universitat Rovira i Virgili
Journal publication year: 2018
Publication Type: Journal Publications
Repositori URV